Scribe Therapeutics, Inc. (SCTX)
16.00
+0.52
(+3.36%)
USD |
NASDAQ |
Nov 06, 10:20
Scribe Therapeutics Enterprise Value : 413.68M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 413.68M |
| November 04, 2026 | 438.29M |
| November 03, 2026 | 427.31M |
| November 02, 2026 | 414.82M |
| October 30, 2026 | 412.54M |
| October 29, 2026 | 450.79M |
| October 28, 2026 | 452.68M |
| October 27, 2026 | 422.77M |
| October 26, 2026 | 415.95M |
| October 23, 2026 | 412.26M |
| October 22, 2026 | 460.63M |
| October 21, 2026 | 486.00M |
| October 20, 2026 | 495.65M |
| October 19, 2026 | 487.70M |
| October 16, 2026 | 500.77M |
| October 15, 2026 | 512.88M |
| October 14, 2026 | 513.83M |
| October 13, 2026 | 482.59M |
| October 12, 2026 | 511.94M |
| October 09, 2026 | 521.40M |
| October 08, 2026 | 484.67M |
| October 07, 2026 | 453.25M |
| October 06, 2026 | 429.77M |
| October 05, 2026 | 427.50M |
| October 02, 2026 | 438.48M |
| Date | Value |
|---|---|
| October 01, 2026 | 445.77M |
| September 30, 2026 | 469.05M |
| September 29, 2026 | 556.61M |
| September 28, 2026 | 532.76M |
| September 25, 2026 | 523.48M |
| September 24, 2026 | 529.73M |
| September 23, 2026 | 622.88M |
| September 22, 2026 | 652.03M |
| September 21, 2026 | 651.65M |
| September 18, 2026 | 745.36M |
| September 17, 2026 | 729.08M |
| September 16, 2026 | 671.53M |
| September 15, 2026 | 719.99M |
| September 14, 2026 | 677.59M |
| September 11, 2026 | 683.65M |
| September 10, 2026 | 678.53M |
| September 09, 2026 | 677.40M |
| September 08, 2026 | 713.94M |
| September 04, 2026 | 663.39M |
| September 03, 2026 | 703.90M |
| September 02, 2026 | 705.61M |
| September 01, 2026 | 669.64M |
| August 31, 2026 | 698.79M |
| August 28, 2026 | 659.03M |
| August 27, 2026 | 666.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 6.561B |
| Twist Bioscience Corp. | 7.486B |
| Veracyte, Inc. | 1.599B |
| Cypherpunk Technologies, Inc. | 258.59M |
| Nurix Therapeutics, Inc. | 637.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.477M |
| Revenue (Quarterly) | 1.918M |
| Total Expenses (Quarterly) | 8.395M |
| EPS Diluted (Quarterly) | -0.3421 |
| Gross Profit Margin (Quarterly) | 59.07% |
| Profit Margin (Quarterly) | -337.7% |
| Earnings Yield | -12.79% |
| Normalized Earnings Yield | -12.85 |